Medivir AB (OSTO:MVIR)

kr 2.87 0.08 (2.87%) Market Cap: 321.92 Mil Enterprise Value: 165.94 Mil PE Ratio: 0 PB Ratio: 2.27 GF Score: 53/100

Q3 2024 Medivir AB Earnings Call Transcript
Nov 06, 2024

kr2.89 (+0.35%)

Earnings
Q2 2024 Medivir AB Earnings Call Transcript
Aug 22, 2024

kr3.06 (-3.16%)

Earnings
Q4 2023 Medivir AB Earnings Call Transcript
Feb 15, 2024

kr2.97 (+3.31%)

Earnings
Medivir AB to Discuss the Updated Data in Advanced Hepatocellular Carcinoma Call Transcript
Jan 23, 2024
Q3 2023 Medivir AB Earnings Call Transcript
Oct 27, 2023

kr5.73 (-10.26%)

Earnings
Q2 2023 Medivir AB Earnings Call Transcript
Aug 18, 2023

kr6.06 (-1.29%)

Earnings
Q1 2023 Medivir AB Earnings Call Transcript
Apr 27, 2023

kr6.11

Earnings
Q4 2022 Medivir AB Earnings Call Transcript
Feb 15, 2023

kr7.05 (-3.37%)

Earnings
Medivir AB at Redeye Fight Cancer Day (Virtual) Transcript
Jan 19, 2023
Q3 2022 Medivir AB Earnings Call Transcript
Nov 03, 2022

kr6.61 (+0.75%)

Earnings
Q2 2022 Medivir AB Earnings Call Transcript
Aug 19, 2022

kr6.67 (+3.83%)

Earnings
Q1 2022 Medivir AB Earnings Call Transcript
Apr 28, 2022

kr6.54 (+1.01%)

Earnings
Q4 2021 Medivir AB Earnings Call Transcript
Feb 15, 2022

kr6.84 (+1.21%)

Earnings
Q3 2021 Medivir AB Earnings Call Transcript
Nov 03, 2021

kr7.66 (+1.85%)

Earnings
Medivir AB to Discuss Update on the Progress and Plans for the MIV-818 Program Call Transcript
Sep 16, 2021
Q2 2021 Medivir AB Earnings Call Transcript
Aug 19, 2021

kr8.47 (-4.26%)

Earnings
Q1 2021 Medivir AB Earnings Call Transcript
Apr 28, 2021

kr6.55 (+1.27%)

Earnings
Q4 2020 Medivir AB Earnings Call Transcript
Feb 26, 2021

kr6.88 (+0.84%)

Earnings
Medivir AB to Discuss Exclusive Licensing Agreement with IGM Biosciences for Birinapant Call Transcript
Jan 12, 2021
Q3 2020 Medivir AB Earnings Call Transcript
Nov 10, 2020

kr9.15 (-0.73%)

Earnings
Q2 2020 Medivir AB Earnings Call Transcript
Aug 20, 2020

kr9.55 (+1.57%)

Earnings
Q1 2020 Medivir AB Earnings Call Transcript
May 05, 2020

kr10.05 (-4.96%)

Earnings
Medivir AB R&D Day Transcript
Mar 02, 2020
Q4 2019 Medivir AB Earnings Call Transcript
Feb 13, 2020

kr9.74 (-0.14%)

Earnings
Q3 2019 Medivir AB Earnings Call Transcript
Nov 27, 2019

kr14.77 (+2.09%)

Earnings
Q2 2019 Medivir AB Earnings Call Transcript
Aug 28, 2019

kr16.15 (-1.64%)

Earnings
Medivir AB to Discuss the Development of Phase IA Study with MIV-818 Call Transcript
Jun 13, 2019
Q1 2019 Medivir AB Earnings Call Transcript
May 03, 2019

kr11.95 (+2.19%)

Earnings

Medivir AB to Discuss the Updated Data in Advanced Hepatocellular Carcinoma Call Transcript

Jan 23, 2024 / 01:00PM GMT

Release Date Price: kr2.89 (+4.59%)

Transcript

Operator

This call is being recorded. Welcome to Medivir press conference. For the first part of the conference call, the participants will be in listen only mode. (Operator Instructions) Now I will hand the conference over to CEO, Jens Lindberg. Please go ahead.

Jens Lindberg

Medivir AB - Chief Executive Officer

Thank you. Good afternoon, and welcome, everyone. My name is Jens Lindberg, I'm the CEO of Medivir. I am joined for today's call by our Chief Medical Officer, Pia Baumann, as well as our Chief Scientific Officer, Fredrik Ãberg, and Magnus Christensen, our CFO. Today's call, we will follow up on the events at last week when we presented our first data for fostrox + Lenvima at a scientific congress at ASCO GI in San Francisco. And go through the data, and also what that means, implications for our plans going forward.

So we are now back in Sweden after a very energizing week with a lot of interactions with global experts in the field of hepatocellular carcinoma. And in the call today, we will focus on three elements. We'll start off with a bit of a sort

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.